Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 362 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Electrocardiogram (ECG) Clear all

Conditions: Pancreatic Acinar Cell Carcinoma
Interventions: Olaparib, ECG, CT CAP, Tumor Biopsy; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kita-kyushu Lung Cancer Antigen 1, Human
Interventions: IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine; Drug · Biological · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: No Specific Medical Conditions or Disease States, No Specific Conditions
Interventions: Device: Telemetry monitoring; Device
Lead sponsor: Turtle Shell Technologies Pvt. Ltd.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Midland, Texas

Conditions: Pediatric ALL
Interventions: ECG; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 45 Days
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Atrial Fibrillation (AF)
Interventions: Electrocardiogram recording; Device
Lead sponsor: Whoop Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Covina, California • Northridge, California + 4 more

Conditions: Hypertension, Cardiovascular Diseases, Cardiovascular Risk Factors, Circadian Rhythms, Sleep
Interventions: At-home Polysomnography, Circadian Protocol, Rested Wakefulness Trial, Overnight Sleep Trial, Regularized Sleep Schedule; Other · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 25 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Aortic Stenosis
Interventions: Portable 1-lead electrocardiogram, Point-of-care ultrasound, AI-ECG risk algorithm, AI-POCUS; Diagnostic Test · Other
Lead sponsor: Yale University; Other
Eligibility: 70 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: New Haven, Connecticut • New York, New York • Houston, Texas

Conditions: Healthy
Interventions: Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiovascular Diseases
Interventions: Brachial artery ultrasound imaging; Procedure
Lead sponsor: Everist Genomics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Derby, Connecticut • Milwaukee, Wisconsin

Conditions: Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions: Trastuzumab Deruxtecan, Datopotamab Deruxtecan; Drug
Lead sponsor: Ana C Garrido-Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more

Conditions: Healthy, Cerebrovascular Accident
Interventions: Electrocardiogram; Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ECG Effects
Interventions: Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chest Pain
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Atrial Fibrillation
Interventions: Metformin, Recommendations for lifestyle modification., AliveCor; Drug · Behavioral · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atrial Fibrillation
Interventions: Verily Watch Cardio, iRhythm Zio monitor, Schiller CARDIOVIT FT-1; Device
Lead sponsor: Verily Life Sciences LLC; Industry
Eligibility: 22 Years and older
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Lakewood, Colorado • Southfield, Michigan • Winston-Salem, North Carolina

Conditions: Fetal Arrhythmia, Abnormality in Fetal Heart Rate or Rhythm, Long QT Syndrome
Interventions: magnetocardiography, postnatal ECG, fetal echocardiography; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sepsis, Emergency Medical Services, Quality Improvement, Shock, Septic, Fluid Therapy
Interventions: Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol, Conventional Prehospital Suspected Sepsis Protocol; Other
Lead sponsor: Orange Park Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orange Park, Florida

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Huntleigh Healthcare Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Myocardial Infarction
Interventions: SmartLink Wireless Monitoring System (K033642); Device
Lead sponsor: Welch Allyn; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 7
States / cities: Salinas, California • Gainesville, Florida • Miami, Florida + 3 more

Conditions: Malignant Digestive System Neoplasm
Interventions: Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride, Electrocardiogram, Fluorouracil, Holter Monitoring, Isosorbide Mononitrate, Medical Device Usage and Evaluation, Placebo Administration, Questionnaire Administration; Procedure · Drug · Device + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Hypertension
Interventions: Use of Eko DUO stethoscope (paired ECG/PCG); Device
Lead sponsor: Eko Devices, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Providence, Rhode Island

Conditions: Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia, Arrhythmia
Interventions: Electrocardiogram (ECG); Diagnostic Test
Lead sponsor: HeartBeam, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers, Narcolepsy Type 1
Interventions: Portable EEG Device, Portable ECG Device, Accelerometry; Device
Lead sponsor: Takeda; Industry
Eligibility: 16 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Redwood City, California • Colorado Springs, Colorado • Clearwater, Florida + 9 more

Search by objective public record fields.

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Validating Dozee for Contactless Monitoring of Heart, Breathing, and Movemen

Umbilical Vessel Catheterization Under ECG Monitoring and Guidance

WHOOP ECG Software Performance Assessment Study

Sleep and Circadian Mechanisms in Hypertension

Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

Brachial Artery Ultrasound Imaging: A Repeatability Study

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Improvement of Use Dependent Plasticity in Chronic Stroke Patients

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

Prognosis of Very Low Dose SPECT

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

Verily Watch Cardio (AF and ECG) Study

Fetal and Neonatal Magnetophysiology

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Orange Park Out-of-Hospital Quality Improvement Study for Improving CMS Sepsis Core Measures

Fetal Electrocardiogram Extraction-Pilot Study

Pre-Hospital Wireless Transmission of Electrocardiograms to a Cardiologist Via a Hand-Held Device

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope

HeartBeam ECG Registry

Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants